甲氨蝶呤是维持全秃患者头发再生的有效且安全的治疗方法吗?一项严格评价的主题
本文通过检索PubMed、Ovid MEDLINE、Ovid Embase和Cochrane Central(2017年10月),纳入2项前瞻性研究和11项回顾性病例系列,共226例基线脱发30%至全秃的患者,评估甲氨蝶呤(MTX)诱导和维持头发再生的证据。MTX通常与全身性糖皮质激素联用于诱导再生而非维持。再生(定义为50%至完全再生)报告于20-90%的患者,复发率为20-80%,不良反应为7%-60%。证据不足以确定MTX是否可用于维持广泛性斑秃的再生。
要点
- MTX常与全身性糖皮质激素联用于诱导头发再生,而非维持再生。
- 再生(50%至完全再生)报告于20-90%的患者,复发率为20-80%,不良反应为7%-60%。
- 证据不足以确定MTX对维持广泛性斑秃再生是否有用,纳入的病例系列存在高偏倚风险。
核心结论
- 证据不足以确定MTX是否可用于维持广泛性斑秃的再生。
- 一些证据提示MTX与全身性糖皮质激素联用可能诱导头发再生,但难以将应答归因于任一治疗或自发再生。
- 作者认为对于严重影响生活质量的严重疾病患者,偶尔可考虑MTX。
研究设计与样本
- 严格评价的主题,检索PubMed、Ovid MEDLINE、Ovid Embase和Cochrane Central(2017年10月)。
- 纳入2项前瞻性研究和11项回顾性病例系列,共226例基线脱发30%至全秃的患者。
主要发现
- MTX通常与全身性糖皮质激素联用于诱导头发再生而非维持再生。
- 再生(定义为50%至完全再生)报告于20-90%的患者。
- 复发率为20-80%,再治疗时再生情况不一。
- 不良反应范围为7%-60%。
- 大多数系列样本量小,方法学细节和随访数据有限。
关键数值与推荐
- 再生定义为50%至完全再生,报告于20-90%的患者。
- 复发率为20-80%。
- 不良反应范围为7%-60%。
临床怎么用
- 作者认为对于严重影响生活质量的严重疾病患者,偶尔可考虑MTX。
- 需要随机对照试验评估MTX单用或与糖皮质激素联用对比安慰剂对诱导和/或维持头发再生缓解的作用。
局限性
- 大多数系列样本量小,方法学细节和随访数据有限。
- 难以将应答归因于任一治疗或自发再生。
- 纳入的病例系列存在高偏倚风险。
- 证据不足以确定MTX是否可用于维持广泛性斑秃的再生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CLINICAL QUESTION/SCENARIO: Is methotrexate (MTX) an effective and safe treatment for maintaining hair regrowth in people with alopecia totalis? BACKGROUND: Alopecia areata (AA) is a common disorder causing nonscarring hair loss with an estimated lifetime prevalence of approximately 2%. Treatment of extensive AA is challenging. The aim of this Critically Appraised Topic was to assess the current evidence regarding use of MTX for inducing and maintaining hair growth in patients with alopecia totalis. METHODS: We critically appraised the literature identified from searching PubMed, Ovid MEDLINE, Ovid Embase and Cochrane Central (October 2017), using the search terms ("alopecia areata" OR "alopecia totalis" OR "alopecia universalis") AND (methotrexate). RESULTS/IDENTIFIED EVIDENCE: Two prospective studies and 11 retrospective case series were included, comprising 226 patients with alopecia varying from 30% hair loss to alopecia universalis at baseline. MTX was usually given with systemic corticosteroids for induction of hair regrowth rather than regrowth maintenance. Regrowth, defined as anything from 50% to complete regrowth, was reported in 20-90% of patients. Relapse occurred in 20-80%, with variable regrowth on retreatment. Most series were small, with limited methodological detail and follow-up data. Adverse effects ranged from 7% to 60%. DISCUSSION AND RECOMMENDATION FOR CLINICAL CASE: We found insufficient evidence to conclude whether MTX is useful for maintaining regrowth in extensive AA. We found some evidence to suggest that hair regrowth may be induced by MTX when used in combination with systemic corticosteroids, but it was difficult to attribute responses to any one treatment or spontaneous regrowth. Included case series were at a high risk of bias. Randomized controlled trials are needed to evaluate whether MTX alone, or in combination with corticosteroids, vs. placebo is useful for inducing and/or maintaining remission of hair regrowth. In the meantime, MTX may occasionally be considered in people with severe disease that significantly impacts on their quality of life.
引用
- Browne R, Stewart L, Williams HC, et al. Is methotrexate an effective and safe treatment for maintaining hair regrowth in people with alopecia totalis? A Critically Appraised Topic. Br J Dermatol. 2018. PMID: 29777625. doi:10.1111/bjd.16796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。